NASDAQ:PSTX - Poseida Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.67
  • Forecasted Upside: 796.79 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.97
▼ -0.02 (-1.01%)

This chart shows the closing price for PSTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Poseida Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSTX

Analyst Price Target is $17.67
▲ +796.79% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Poseida Therapeutics in the last 3 months. The average price target is $17.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 796.79% upside from the last price of $1.97.

This chart shows the closing price for PSTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Poseida Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Cantor FitzgeraldInitiated CoverageBuy$24.00Medium
5/13/2022BTIG ResearchLower Price TargetBuy$40.00 ➝ $20.00Low
5/13/2022Piper SandlerLower Price Target$19.00 ➝ $9.00High
5/9/2022Cantor FitzgeraldReiterated RatingOverweightLow
2/18/2022Cantor FitzgeraldInitiated CoverageBuy$24.00High
1/7/2022Cantor FitzgeraldInitiated CoverageOverweight$24.00High
10/12/2021Piper SandlerBoost Price TargetOverweight$17.00 ➝ $19.00High
8/13/2021William BlairReiterated RatingOutperformHigh
5/17/2021BTIG ResearchInitiated CoverageBuy$40.00High
12/7/2020William BlairReiterated RatingBuyHigh
9/16/2020William BlairReiterated RatingBuyHigh
8/18/2020William BlairInitiated CoverageBuyMedium
8/4/2020Bank of AmericaInitiated CoverageBuy$20.00High
8/4/2020William BlairInitiated CoverageOutperformHigh
8/4/2020Piper SandlerInitiated CoverageOverweight$30.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/26/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/25/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Poseida Therapeutics logo
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.97
Low: $1.82
High: $2.12

50 Day Range

MA: $3.48
Low: $1.87
High: $5.03

52 Week Range

Now: $1.97
Low: $1.82
High: $11.10

Volume

189,408 shs

Average Volume

176,071 shs

Market Capitalization

$123.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of Poseida Therapeutics?

The following Wall Street research analysts have issued research reports on Poseida Therapeutics in the last twelve months: BTIG Research, Cantor Fitzgerald, Piper Sandler, William Blair, and Zacks Investment Research.
View the latest analyst ratings for PSTX.

What is the current price target for Poseida Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Poseida Therapeutics in the last year. Their average twelve-month price target is $17.67, suggesting a possible upside of 796.8%.
View the latest price targets for PSTX.

What is the current consensus analyst rating for Poseida Therapeutics?

Poseida Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSTX will outperform the market and that investors should add to their positions of Poseida Therapeutics.
View the latest ratings for PSTX.

How do I contact Poseida Therapeutics' investor relations team?

Poseida Therapeutics' physical mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The company's listed phone number is 858-779-3100. The official website for Poseida Therapeutics is www.poseida.com. Learn More about contacing Poseida Therapeutics investor relations.